ANI Pharmaceuticals ANIP 深 滬
已收盤 08-07 16:00:00 美东时间
78.25
-4.380
-5.30%
華盛通- 最 高78.59
- 今 開77.09
- 成交量 102.01万股
- 最 低 74.33
- 昨 收 82.63
- 總市值 17.80亿
- 52周最高 99.50
- 市盈率 靜 23.54
- 換手率 4.48%
- 52周最低 70.15
- 委 比 52.27%
- 總股本 2274.55万
- 歷史最高 99.50
- 量 比 2.76
- 振 幅 5.16%
- 歷史最低 0.80
- 每 手 1
- 風險率 6.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
08-08 02:26
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:25
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:21
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est
ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140 billion vs $1.119 billion estimate.
08-07 18:53
ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 by 7.8 percent. This is a 22.78 percent increase over earnings of $1.80 per share from the same period last year. The company reported quarterly sales of $266.044 milli...
08-07 18:50
NuGen Medical Devices signs LOI to acquire Sol-Millennium Canada
NuGen Medical Devices (NGMD:CA) signed a non-binding letter to acquire 100% of Sol-Millennium Canada. Under the proposed deal, SolM HK would own ~65% of the combined company, while existing NuGen shar...
08-06 21:23
ANI Pharmaceuticals Q2 2026 Earnings Preview
ANI Pharmaceuticals (ANIP) is scheduled to announce Q2 earnings results on Friday, August 7th, before market open. The consensus EPS Estimate is $2.04 (+13.3% Y/Y) and the consensus Revenue Estimate i...
08-06 21:21
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
ANI Pharmaceuticals announced it will release its second-quarter 2026 financial results on August 7, 2026, at 8:00 a.m. ET. The event will include a webcast and conference call hosted by Nikhil Lalwani, President and CEO; Stephen P. Carey, CFO; and Chris Mutz, Head of Rare Disease. The webcast can be accessed via the provided links, with a replay available for up to one year. ANI is a diversified biopharmaceutical company focused on rare disease,...
07-24 10:50
美股大行评级 | 台积电、联合健康、美国合众银行获多家大行上调目标价；奈飞、直觉外科遭数十家大行下调目标价
今日重点评级关注：摩根大通：维持联合大陆航空"超配"评级，目标价从156美元升至203美元；摩根士丹利：维持联合大陆航空"超配"评级，目标价从185美元升至190美元
07-20 13:49
美股大行评级 | 潜在涨幅98.68%！DA Davidson上调Almonty Industries目标价至33美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持Almonty Industries"买入"评级，目标价从25美元升至33美元；Stifel：维持Nurix Therapeutics"买入"评级，目标价从34美元升至40美元
07-13 10:13
